Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor. In vivo effects on blood 2′-deoxyguanosine in primates

International Immunopharmacology

Volumn 3, Issue 4, 2003, Pages 541-548

  Kilpatrick, J Michael ^a   Morris, Philip E ^b   Serota Jr , David G ^b   Phillips, Deborah ^b   Moore II, D Ray ^b   Bennett, J Claude ^b   Babu, Y S ^b  

^a BIOCRYST PHARMACEUTICALS INC   (United States)

^b NONE

Author keywords

2 Deoxyguanosine; Activated T cell inhibition; dGTP; Inosine; Pharmacodynamics; Pharmacokinetics; PNP inhibition; Purine nucleoside phosphorylase

Indexed keywords

1,4 DIDEOXY 1 C (4 HYDROXYPYRROLO[3,2 D]PYRIMIDIN 7 YL) 1,4 IMINO DEXTRO RIBITOL; DEOXYGUANOSINE; IMMUCILLIN H; PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; IN VIVO STUDY; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL;

EID: 0037390138     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(03)00044-4     Document Type: Article

References (32)

1. Miles R.W., Tyler R.C., Funeaux R.H., Bagdassarian C.K., Schramm V.L. One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase. Biochemistry. 37:1998;8615-8621.
2. Parks R.E. Jr., Stoeckler J.D., Cambor D., Savarese T.M., Crabtree G.W., Chu S.-H. Purine nucleoside phosphorylase and 5′-methylthioadenosine phosphorylase: targets for chemotherapy. Sartorelli A., Lazo J.S., Bertino J.R. Molecular actions and targets for cancer chemotherapeutic agents. 1981;229-252 Academic Press, New York.
3. Stoeckler J.D. Purine nucleoside phosphorylase: a target for chemotherapy. Glazer R.I. Developments in cancer chemotherapy. 1984;35-60 CRC Press, Boca Raton.
4. Erion M.D., Takabayashi K., Smith H.B., Kessi J., Wagner S.et al. Purine nucleoside phosphorylase: 1. Structure-function studies. Biochemistry. 36:1997;11725-11734.
5. Erion M.D., Stoeckler J.D., Guida W.C., Walter R.L., Ealick S.E. Purine nucleoside phosphorylase: 2. Catalytic mechanism. Biochemistry. 36:1997;11735-11748.
6. Stoeckler J.D., Poirot A.F., Smith R.M., Parks R.E. Jr., Ealick S.E.et al. Purine nucleoside phosphorylase: 3. Reversal of purine based specificity by site-directed mutagenesis. Biochemistry. 36:1997;11749-11756.
7. Markert M.L. Purine nucleoside phosphorylase deficiency. Immunodefic. Rev. 3:1991;45-81.
8. Morris P.E., Montgomery J.A. Inhibitors of the enzyme purine nucleoside phosphorylase. Exp. Opin. Ther. Patents. 8:1998;283-284.
9. Giblett E.R., Ammann A.J., Wara D.W., Sandman R., Diamond L.K. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet. 1:1975;1010-1013.
10. Otterness I.G., Bliven M.L. The T cell as a therapeutic target. Rainsford K.D., Velo G.P. New developments in antirheumatic therapy. 1989;277-304 Kluwer Academic Publishing, Norwell, MA.
11. St. Georgiev V. Enzymes of the purine metabolism: inhibition and therapeutic potential. Ann. N. Y. Acad. Sci. 685:1993;207-216.
12. Busse W.W., Lemanske R.F. Jr. Asthma. N. Engl. J. Med. 344:2001;350-362.
13. Paquette D.W., Williams R.C. Modulation of host inflammatory mediators as a treatment strategy for periodontal diseases. Periodontology. 24:2000;239-252.
14. Ullman B., Gudas L.J., Clift S.M., Martin D.W. Jr. Isolation and characterization of purine-nucleoside phosphorylase-deficient T-lymphoma cells and secondary mutants with altered ribonucleotide reductase: genetic model for immunodeficiency disease. Proc. Natl. Acad. Sci. U. S. A. 76:1979;1074-1078.
15. Bantia S., Montgomery J.A., Johnson H.G., Walsh G.M. In vivo and in vitro pharmacologic activity of the purine nucleoside phosphorylase inhibitor BCX-34: the role of GTP and dGTP. Immunopharmacology. 35:1996;53-63.
16. Singhal R.L., Yeh Y.A., Szekeres T., Weber G. Increased deoxycytidine kinase activity in cancer cells and inhibition by difluorodeoxycytidine. Oncol. Res. 4:1992;517-522.
17. Kawasaki H., Carrera C., Carson D. Quantitative immunoassay of human deoxycytidine kinase in malignant cells. Anal. Biochem. 207:1992;193-196.
18. Kreis W., Arlin Z., Yagoda A., Leyland-Jones B., Fiori L. Deoxycytidine and deoxythymidine kinase activities in plasma of mice and patients with neoplastic disease. Cancer Res. 42:1982;2514-2517.
19. Spasokoukotskaja T., Arner E.S., Brosjo O., Gunven P., Juliusson G.et al. Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues. Eur. J. Cancer. 31A:1995;202-208.
20. Eriksson S., Arner E., Spasokoukotskaja T., Wang L., Karlsson A.et al. Properties and levels of deoxynucleoside kinases in normal and tumor cells; implications for chemotherapy. Adv. Enzyme Regul. 34:1994;13-25.
21. Ho A.D., Knauf W., Ganeshaguru K., Hunstein W., Hoffbrand A.V. Purine degradative enzymes in circulating malignant cells of patients with chronic B cell neoplasia. Hematol. Oncol. 5:1987;9-17.
22. Kawasaki H., Carrera C.J., Piro L.D., Saven A., Kipps T.J.et al. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood. 81:1993;597-601.
23. Bantia S., Miller P.J., Parker C., Ananth S.L., Horn L.L.et al. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H) - a novel potent and orally active immunosuppressive agent. Int. Immunopharm. 1:2001;1199-1210.
24. Kicska G.A., Long L., Hörig H., Fairchild C., Tyler P.C.et al. Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 98:2001;4593-4598.
25. Viegas T.X., Omura G.A., Stoltz R.R., Kisicki J. Pharmacokinetics and pharmacodynamics of Peldesine (BCX-34), a purine nucleoside inhibitor following single and multiple oral doses in healthy volunteers. J. Clin. Pharmacol. 40:2000;410-420.
26. Duvic M., Olsen E.A., Omura G.A., Maize J.C., Vonderheid E.C.et al. A phase III, randomized, double blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. 44:2001;940-947.
27. Viegas T.X., Kilpatrick J.M., Warren T.S., Omura G.A. Endogenous purine nucleosides with potential clinical applications. J. Clin. Pharmacol. 41:2001;1031.
28. Evans G.B., Furneaux R.H., Hutchison T.L., Kezar H.S., Morris P.E. Jr.et al. Addition of lithiated 9-deazapurine derivatives to a carbohydrate cyclic imine: convergent synthesis of the aza-C-nucleoside immucillins. J. Org. Chem. 66:2001;5723-5730.
29. Gilbertsen R.B., Dong M.K. Blockade of nucleoside degradation in monkey whole blood in vitro by CI-1000, a purine nucleoside phosphorylase (PNP) inhibitor. Sahota A., Taylor M. Purine and pyrimidine metabolism in man VIII. 1995;171-195 Plenum, New York.
30. Robertson D.G., Urda E.R., Bleavins M.R., Lalwani N.D. Changes in monkey plasma purines induced by repeated doses of CI-1000, a novel inhibitor of purine nucleoside phosphorylase. Sahota A., Taylor M. Purine and pyrimidine metabolism in man VIII. 1995;173-177 Plenum, New York.
31. Hallak H., Hayes A., Dong M., Gilbertsen R., Guttendorf R. Pharmacokinetics/Pharmacodynamics of CI-1000, a purine nucleoside phosphorylase (PNP) inhibitor in rats and monkeys. Sahota A., Taylor M. Purine and pyrimidine metabolism in man VIII. 1995;161-165 Plenum, New York.
32. Moriwaki Y., Yamamoto T., Higashino K. Enzymes involved in purine metabolism - a review of histochemical localization and functional implications. Histol. Histopathol. 14:1999;1321-1340.